InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,267.84
(
-0.74%
)
US TECH 100
18,152.40
(
-0.42%
)
Dow Jones
39,065.26
(
-1.53%
)
Brent Oil
81.31
(
-0.27%
)
Bitcoin
67,924.58
(
-1.71%
)
Post# of 251921
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119685
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 180759

Wednesday, 11/12/2014 12:51:08 PM

Wednesday, November 12, 2014 12:51:08 PM

Post# of 251921
Phase-2 data on Sovaldi + GS-5816 show why only 12w regimens were advanced to phase-3 by GILD:

http://finance.yahoo.com/news/gilead-announces-phase-2-data-130000472.html

The results…presented at the Liver Meeting this week (Oral #80), evaluated eight weeks of SOF plus GS-5816, with and without RBV, in patients with genotype 1 or 2 HCV infection. Among genotype 1 patients receiving SOF plus GS-5816 100 mg, SVR12 rates were 81 percent (n=25/31) and 90 percent (n=26/29), with and without RBV, respectively.

81-90% SVR12 isn’t good enough anymore.

In short, Sovaldi + GS-5816 will be an improvement relative to Harvoni only for GT3 patients.

See cheat sheet in #msg-104733739 for the Sovaldi + GS-5816 phase-3 program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up